Johnson & Johnson (JNJ)
Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating
Johnson & Johnson offers a unique blend of steady growth, portfolio depth, and resilience, distinguishing it from both AI-driven and pharma peers. JNJ's diversified pharma and MedTech assets underpin robust revenue growth, with 28 platforms generating $1bn+ annually and 13 pharma brands growing double digits. I expect JNJ to deliver reliable 9% annual returns, driven by 8% EPS growth, a 2.4% dividend yield, and disciplined capital allocation.
Pharma Momentum Fuels Johnson & Johnson's Path to Double-Digit Upside
Our Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) 24/7 Wall St.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?
J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Johnson & Johnson (JNJ) reached $228.39 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
Johnson & Johnson (JNJ) closed at $240.87 in the latest trading session, marking a +1.07% move from the prior day.
3 No-Brainer Dividend Growth Stocks to Buy in June
With the rate environment stabilizing in mid-2026, income investors are circling back to a familiar playbook: own the businesses that have raised payouts through every cycle in living memory.
I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow
I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one.
Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a rare long-duration compounder because it is the rare equity whose credit quality, dividend record, and demand profile collectively rival a sovereign bond while still compounding capital.
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
Joaquin Duato said finding a cure for certain cancers and turning others into chronic diseases is an achievable target for the coming decade.
Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
